S. typhi

Some of the pathogens in Table 2, infect only humans (e.g., Vibrio cholerae. Salmonella typhi. Shigella dysenteriae, poliovirus, hepatitis A virus), whereas others, known as zoonotic, infect both humans and animals Salmonella no thypi. Shigella no dysenteriae, Campylobacter, enteropathogenic Escherichia coli such as for example the biotype 0157 H7, Cryptosporidium, etc.). The control of those that only infect humans is easier than the control of the zoonotic ones. Thus, some of them (S, typhi, S. dysenteriae, poliovirus, etc.) have practically been eradicated in many developed countries, whereas the eradication, and even the control below certain levels, of the zoonotic ones is a very difficult task. 

Three typhoid vaccines are available currently for use in the United States (1) an oral live-attenuated vaccine (Vivotif Berna-TM vaccine, Swiss Serum and Vaccine Institute), (2) a parenteral heat-phenol-inactivated vaccine (Typhoid Vaccine, Wyeth-Ayerst), and (3) a parenteral capsular polysaccharide vaccine (Typhim Vi, Pasteur Merieux). Immunization is recommended only for travelers going to endemic areas such as Latin America, Asia, and Africa household contacts of a chronic carrier and laboratory personnel who frequently work with S. typhi.13... 

S. typhi muri urn (plate incorporation) + - Lijinsky and Andrews 1980... 

S. typhi muri urn (liquid preincubation) + + Zeiger and Haworth 1985... 

Gene mutations S. typhi muri am (mouse host mediated) Lambotte-Vandepaer et al. 1980... 

CDC Case Definition An illness caused by S. typhi that is often characterized by insidious onset of sustained fever, headache, malaise, anorexia, relative bradycardia, constipation or diarrhea, and nonproductive cough. However, many mild and atypical infections occur. Carriage of S. typhi may be prolonged. Laboratory criteria for diagnosis is isolation of S. typhi from blood, stool, or other clinical specimen. 

Some patients may continue to shed Salmonella for 1 year or longer. These chronic-carrier states are rare for serotypes other than S. typhi. 

A representative of a pentaacyl lipid A, in which the only secondary fatty acid present is associated with GlcN(I), is precursor lb (Fig. 9 B). This compound was isolated from a temperature-sensitive mutant of S. typhi-murium (mutant Ts5) (173). The only 3-acyloxyacyl residue in precursor lb is 14 O[3-0(16 O)], which is amide-linked to GlcN (I) (position 2). 

S typhi muri urn (modified Ames assay) Gene mutation... 

Typhoid fever caused by Salmonella typhi or S. paratyphi is an important and prevalent cause of continuous fever without localizing symptoms in the tropics. The diagnosis can be confirmed with a bloodculture. Response on therapy is often seen only after 3 days when the fever subsides. Chloramphenicol-resistant Salmonella typhi was first described in Vietnam in 1973. Its prevalence reached 95% in the 1970s and then decreased to 54% in the 1980s after cotrimoxazole became the treatment of choice. In the mid-1993, there was a dramatic increase in the number of strains of S. typhi, isolated in the hospital and from patients in the outbreaks, which are resistant to the three first-line antibiotics chloramphenicol, cotrimoxazol and ampicillin. This indicated that there was an urgent need for effective antibiotics for the treatment of typhoid fever. 

Because of bone marrow toxicity of chloramphenicol, its use is restricted to the treatment of infection caused by S. typhi and paratyphi (treatment of typhoid fever). 

Enterobacter,c Proteus, Yersinia (Y. pestis, plague), Escherichia, Klebsiella, Salmonella (S. typhi, typhoid fever), Serratia, Shigella (S. dysenteriae, bacterial dysentery), Haemophilus Vibrio (V. cholerae, Asiatic cholera) Zym.om.onas... 

The observed data reveals that these spiro-(3-lactams are antifungal in nature and the introduction of chloro, methyl and methoxy group further enhances the antifungal activity whereas, nitro group reduces it. The spiro-(3-lactams I were also found to exhibit strong antibacterial activity against E. coli, S. typhi, and B. aureus. 

Figure 9. Titration of human sera in ELISA against LPSfrom (a) S. paratyphi A (02, 12), (b) S. typhimurium (04,5,12), and(c) S. typhi (09, 12). Key (a,b,c,) B, 12patients with Salmonella serogroup B infection D, 41 patients with Salmonella serogroup D infection and Bd, 36 healthy blood donors. The horizontal bars indicate the 95% confidence limits. (Reproduced with permission from Ref 50. Copyright 1975, Int. Arch.

---